2Dayyani F, Etzelc J, Liu M, et al. Research meta-analysis of the impact of human papiUomavirus(HPV) on cancer risk and over- all survival in head and neck squamous cell carcinomas (HNSCC) [J]. Head and Neck Oncology ,2010,2 : 1 - 15.
3Schlecht NF. Prognostic value of human papillomavirus in the survival of head and neck cancer patients: an overview of the evi- dence [ J ]. Oucol Rep,2005,14 (5) : 1239 - 1247.
4Parmar MK,Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival end points[J]. Stat Med, 1998,17 (24) :2815 - 2834.
5Begg CB, Mazumdar M. Operating characteristics of a rank cor- relation test for publication bias [ J]. Biometrics, 1994,50 ( 4 ) : 1088 - 1101.
6Egger M, Davey SG, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test [ J ]. BMJ, 1997,315 ( 7109 ) : 629 - 634.
7Hong AM,Dobbins TA, Lee CS, et al. Human papillomavims predicts outcome in oropharyngeal cancer in patients treated pri- marily with surgery or radiation therapy[ J]. Br J Cancer,2010, 103(10) :1510 - 1517.
8Hong AM,Dobbins TA,Lee CS,et al. Relationships between epi- dermal growth factor receptor expression and human papillomavirus status as markers of prognosis in oropharyngeal cancer[ J ]. Europe- an Journal of Cancer,2010,46(11) :2088 -2096.
9Nichols AC, Finkelstein DM, Faquin WC, et al. Bcl2 and human papilloma virus 16 as predictors of outcome following concurrent chemoradiation for advanced oropharyngeal cancer [ J ]. Clin Cancer Res,2010,16 (7) :2138 - 2146.
10Jung AC, Briolat J, Millonet R, et al. Biological and clinical rele- vance of transcriptionally active human papillomavirus (HPV) in- fection in oropharynx squamous cell carcinoma [ J ]. Int J Cancer, 2009,126(8) :1882 - 1894.
4Wiest T, Schwarz E, Enders C, et al. Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control. Oncogene, 2002, 21: 1510-1517.
5Castro TP. Bussoloti-Filho I. Prevalence of human papillomavirus (HPV) in oral cavity and oropharynx. Braz J Otorhinolaryngol,2006, 72: 272-282.
6Velyvyte D, Laiskonis A, Uloza V, et al. Prevalence of papillomavirus infection among patients with laryngeal papillomatosis and the effects of some risk factors on the persistence of papillomaviruses in the upper respiratory tract. Medicina (Kaunas), 2002,38 : 499-504.
7Draganov P, Todorov S, Todorov I, et al. Idemification of HPV DNA in patients with juvenile-onset recurrent respiratory papillomatosis using SYBR Green real-time PCR. Int J Pediatr Otorhinolaryngol, 2006,70: 469-473.
8Syrjanen S. Human papillomavirus infections and oral tumors. Med Microbial Immunol, 2003,192 : 123-128.
9Smith EM, Swarnavel S. Prevalence of human papillomavirus (HPV) in oral cavity and oropharynx. Rev Bras Otorrinolaringol, 2006,72: 272-282.
10Campisi G, Panzarella V, Giuliani M, et al. Human papillomavirus: Its identikit and controversial role in oral oncogenesis, premalignant and malignant lesions ( Review). Int J Oncol, 2007,30 : 813-823.
